Genmab A (GMAB) Receivables (2019 - 2026)

Genmab A's (GMAB) quarterly Receivables came in at $968.0 million in Q1 2026, down 17.55% on a QoQ basis from $1.2 billion in Q4 2025.

Genmab A (GMAB) Receivables (2019 - 2026) Analysis & Trends

Genmab A (GMAB) has 5 years of Receivables data on file, last reported at $968.0 million in Q1 2026.

Quarterly Receivables changed N/A year-over-year to $968.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $968.0 million (changed N/A YoY) and the FY2025 annual result came in at $1.2 billion, up 19.92% from the prior year.
Receivables fell to $968.0 million in Q1 2026, from $1.2 billion in the prior quarter.
In the past five years, Receivables ranged from a high of $1.2 billion in Q4 2025 to a low of $786.0 million in Q4 2023.
A 4-year average of $981.0 million and a median of $979.0 million in 2024 frame the typical range for Receivables.
Annual changes were most pronounced in 2024 — Receivables rose 24.55% — and 2025, when it climbed 19.92%.
Tracing GMAB's Receivables over 4 years: stood at $786.0 million in 2023, then rose by 24.55% to $979.0 million in 2024, then climbed by 19.92% to $1.2 billion in 2025, then dropped by 17.55% to $968.0 million in 2026.
The last three Receivables figures came in at $968.0 million (Q1 2026), $1.2 billion (Q4 2025), and $998.0 million (Q2 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.93 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.06 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	1.84 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	215.33 Mn
10	Genmab A	2.05 Bn	548.77 Mn	1.07 Bn	1.28 Bn

Download Data